PS02.12 Smoking-Related Outcomes of Advanced Stage Lung Cancer Treated with Anti-Programmed Cell Death-1 (PD-1) Therapy: A Single Institution Study: Topic: Pulmonology von Hafiz, M., Naqash, A.R., Stroud, C.R.G., Bowling, M., Walker, P.R.

Volltext

PS02.12 Smoking-Related Outcomes of Advanced Stage Lung Cancer Treated with Anti-Programmed Cell Death-1 (PD-1) Therapy: A Single Institution Study von Hafiz, M., Naqash, A.R., Stroud, C.R.G., Bowling, M., Walker, P.R.

Volltext

OA03.05 Tocilizumab for the Management of Immune Mediated Adverse Events Secondary to PD-1 Blockade: Overall Survival Analysis von Stroud, C.R.G., Hegde, A., Naqash, A.R., Cherry, C., Parent, T., Hardin, J., Walker, P.R.

Volltext

4A.03 Predictive Utility of c-reactive Protein (CRP) in Advanced Stage Lung Cancer Treated with Anti-Programmed Cell Death-1 (PD-1) Therapy: Topic: Medical Oncology von Naqash, A.R., Stroud, C.R.G., Cherry, C., Muzaffar, M., Bowling, M., Walker, P.R.

Volltext

OA03.05 Tocilizumab for the Management of Immune Mediated Adverse Events Secondary to PD-1 Blockade: Overall Survival Analysis: Topic: Medical Oncology von Stroud, C.R.G., Hegde, A., Naqash, A.R., Cherry, C., Parent, T., Hardin, J., Walker, P.R.

Volltext

4A.03 Predictive Utility of c-reactive Protein (CRP) in Advanced Stage Lung Cancer Treated with Anti-Programmed Cell Death-1 (PD-1) Therapy von Naqash, A.R., Stroud, C.R.G., Cherry, C., Muzaffar, M., Bowling, M., Walker, P.R.

Volltext